Antithrombotic Therapy in Chronic Kidney Disease

1 Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12(1):7-11. doi:10.1016/j.kisu.2021.11.003 Open DOISearch in Google Scholar

2 Sundström J, Bodegard J, Bollmann A, et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study. The Lancet Regional Health - Europe. 2022;20:100438. doi:10.1016/J.LANEPE.2022.100438 Open DOISearch in Google Scholar

3 Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation. 2021;143(11):1157-1172. doi:10.1161/CIRCULATIONAHA.120.050686 Open DOISearch in Google Scholar

4 Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C yuan. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-1305. doi:10.1056/NEJMoa041031 Open DOISearch in Google Scholar

5 Vallianou NG, Mitesh S, Gkogkou A, Geladari E. Chronic Kidney Disease and Cardiovascular Disease: Is there Any Relationship? Curr Cardiol Rev. 2019;15(1):55-63. doi:10.2174/1573403X14666180711124825 Open DOISearch in Google Scholar

6 Buckley LF, Schmidt IM, Verma A, et al. Associations Between Kidney Histopathologic Lesions and Incident Cardiovascular Disease in Adults With Chronic Kidney Disease. JAMA Cardiol. 2023;8(4):357-365. doi:10.1001/jamacardio.2023.0056 Open DOISearch in Google Scholar

7 Ocak G, Rookmaaker MB, Algra A, et al. Chronic kidney disease and bleeding risk in patients at high cardiovascular risk: a cohort study. Journal of Thrombosis and Haemostasis. 2018;16(1):65-73. doi:10.1111/jth.13904 Open DOISearch in Google Scholar

8 Sood MM, Bota SE, Mcarthur E, et al. The Three-Year Incidence of Major Hemorrhage among Older Adults Initiating Chronic Dialysis.; 2014. http://www.cjkhd.org/content/1/1/21 Search in Google Scholar

9 Kuo CC, Kuo HW, Lee IM, Lee CT, Yang CY. The Risk of Upper Gastrointestinal Bleeding in Patients Treated with Hemodialysis: A Population-Based Cohort Study.; 2013. http://www.biomedcentral.com/1471-2369/14/15 Search in Google Scholar

10 Liao JN, Chao TF, Liu CJ, et al. Incidence and risk factors for new-onset atrial fibrillation among patients with end-stage renal disease undergoing renal replacement therapy. Kidney Int. 2015;87(6):1209-1215. doi:10.1038/ki.2014.393 Open DOISearch in Google Scholar

11 Official JOurnal Of the InternatiOnal SOciety Of NephrOlOgy KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. www.publicationethics.org Search in Google Scholar

12 Christiansen CF, Schmidt M, Lamberg AL, et al. Kidney disease and risk of venous thromboembolism: a nationwide population-based case-control study. J Thromb Haemost. 2014;12(9):1449-1454. doi:10.1111/jth.12652 Open DOISearch in Google Scholar

13 Wanner C, Herzog CA, Turakhia MP, Conference Steering Committee. Chronic kidney disease and arrhythmias: highlights from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2018;94(2):231-234. doi:10.1016/j.kint.2018.05.005 Open DOISearch in Google Scholar

14 Aursulesei V, Costache II. Anticoagulation in chronic kidney disease: from guidelines to clinical practice. Clin Cardiol. 2019;42(8):774-782. doi:10.1002/clc.23196 Open DOISearch in Google Scholar

15 Pawar P, Kota A, Sen I, et al. Chronic kidney disease and anticoagulation - Quick overview and practical guide. Indian Journal of Vascular and Endovascular Surgery. 2022;9(1):40. doi:10.4103/ijves.ijves_90_21 Open DOISearch in Google Scholar

16 Derebail VK, Rheault MN, Kerlin BA. Role of direct oral anticoagulants in patients with kidney disease. Kidney Int. 2020;97(4):664-675. doi:10.1016/j.kint.2019.11.027 Open DOISearch in Google Scholar

17 Sy J, Hsiung JT, Edgett D, Kalantar-Zadeh K, Streja E, Lau WL. Cardiovascular and Bleeding Outcomes with Anticoagulants across Kidney Disease Stages: Analysis of a National US Cohort. Am J Nephrol. 2021;52(3):199-208. doi:10.1159/000514753 Open DOISearch in Google Scholar

18 Burlacu A, Genovesi S, Ortiz A, et al. Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update. Nephrol Dial Transplant. 2019;34(6):923-933. doi:10.1093/ndt/gfz040 Open DOISearch in Google Scholar

19 Parker K, Thachil J. The use of direct oral anticoagulants in chronic kidney disease. Br J Haematol. 2018;183(2):170-184. doi:10.1111/bjh.15564 Open DOISearch in Google Scholar

20 Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4):S1-S276. doi:10.1016/j.kint.2021.05.021 Open DOISearch in Google Scholar

21 Official JOurnal Of the InternatiOnal SOciety Of NephrOlOgy KDIGO Clinical Practice Guideline for Glomerulonephritis.; 2012. http://www.kidney-international.org Search in Google Scholar

22 Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-1304. doi:10.1136/annrheumdis-2019-215213 Open DOISearch in Google Scholar

23 Dufrost V, Risse J, Zuily S, Wahl D. Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature. Curr Rheumatol Rep. 2016;18(12):74. doi:10.1007/s11926-016-0623-7 Open DOISearch in Google Scholar

24 Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, et al. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial. Ann Intern Med. 2019;171(10):685-694. doi:10.7326/M19-0291 Open DOISearch in Google Scholar

25 Kronbichler A, Leierer J, Shin J Il, et al. Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2019;71(11):1888-1893. doi:10.1002/art.41017 Open DOISearch in Google Scholar

26 Carli G, Farsi A, Chiarini F, Lippolis D, Cortellini G. Hypersensitivity reactions to non-vitamin K oral anticoagulants - a review of literature and diagnostic work-up proposal. Eur Ann Allergy Clin Immunol. 2019;51(1):7-14. doi:10.23822/EurAnnACI.1764-1489.80 Open DOISearch in Google Scholar

27 Huang MJ, Wei RB, Wang Y, et al. Blood coagulation system in patients with chronic kidney disease: A prospective observational study. BMJ Open. 2017;7(5). doi:10.1136/bmjopen-2016-014294 Open DOISearch in Google Scholar

28 Baaten CCFMJ, Schröer JR, Floege J, et al. Platelet Abnormalities in CKD and Their Implications for Antiplatelet Therapy. Clinical Journal of the American Society of Nephrology. 2022;17(1):155-170. doi:10.2215/CJN.04100321 Open DOISearch in Google Scholar

29 Visseren FLJ, MacH F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. doi:10.1093/eurheartj/ehab484 Open DOISearch in Google Scholar

30 Taliercio JJ, Nakhoul G, Mehdi A, et al. Aspirin for Primary and Secondary Prevention of Mortality, Cardiovascular Disease, and Kidney Failure in the Chronic Renal Insufficiency Cohort (CRIC) Study. Kidney Med. 2022;4(11). doi:10.1016/j.xkme.2022.100547 Open DOISearch in Google Scholar

31 Wolfe R, Wetmore JB, Woods RL, et al. Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease. Kidney Int. 2021;99(2):466-474. doi:10.1016/j.kint.2020.08.011 Open DOISearch in Google Scholar

32 Jardine MJ, Ninomiya T, Perkovic V, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: A post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol. 2010;56(12):956-965. doi:10.1016/j.jacc.2010.02.068 Open DOISearch in Google Scholar

33 Goicoechea M, de Vinuesa SG, Quiroga B, et al. Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study). Cardiovasc Drugs Ther. 2018;32(3):255-263. doi:10.1007/s10557-018-6802-1 Open DOISearch in Google Scholar

34 Floyd CN, Passacquale G, Ferro A. Comparative Pharmacokinetics and Pharmacodynamics of Platelet Adenosine Diphosphate Receptor Antagonists and Their Clinical Implications. Search in Google Scholar

35 Frere C, Cuisset T, Quilici J, et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost. 2007;98(4):838-843. Search in Google Scholar

36 Guo LZ, Kim MH, Shim CH, Choi SY, Serebruany VL. Impact of renal impairment on platelet reactivity and clinical outcomes during chronic dual antiplatelet therapy following coronary stenting. Eur Heart J Cardiovasc Pharmacother. 2016;2(3):145-151. doi:10.1093/ehjcvp/pvv052 Open DOISearch in Google Scholar

37 Baber U, Mehran R, Kirtane AJ, et al. Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry. Circ Cardiovasc Interv. 2015;8(6):e001683. doi:10.1161/CIRCINTERVENTIONS.115.001683 Open DOISearch in Google Scholar

38 Geara AS, Ayoub I, Abi Rached J, Siddique MN, Ghimire P, El-Sayegh S. Does hemodialysis affect clopidogrel resistance as measured by VerifyNow P2Y12 test? Am J Cardiol.2011; 107(7):1103-1104. doi:10.1016/j.amjcard.2011.01.003 Open DOISearch in Google Scholar

39 Melloni C, Cornel JH, Hafley G, et al. Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial. Eur Heart J Acute Cardiovasc Care. 2016;5(6):443-454. doi:10.1177/2048872615598631 Open DOISearch in Google Scholar

40 Keltai M, Tonelli M, Mann JFE, et al. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rehabil. 2007;14 (2):312-318.doi:10.1097/01.hjr.0000220582.19516.a6 Open DOISearch in Google Scholar

41 Best PJM, Steinhubl SR, Berger PB, et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J. 2008;155(4):687-693. doi:10.1016/j.ahj.2007.10.046 Open DOISearch in Google Scholar

42 Trimarchi H, Young P, Forrester M, Schropp J, Pereyra H, Freixas E. Clopidogrel diminishes hemodialysis access graft thrombosis. J Vasc Access. 2005;6(1):29-33. doi:10.1177/112972980500600107 Open DOISearch in Google Scholar

43 Ghorbani A, Aalamshah M, Shahbazian H, Ehsanpour A, Aref A. Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients. Indian J Nephrol. 2009;19(2):57-61. doi:10.4103/0971-4065.53323 Open DOISearch in Google Scholar

44 Dember LM, Beck GJ, Allon M, et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA. 2008;299(18):2164-2171. doi:10.1001/jama.299.18.2164 Open DOISearch in Google Scholar

45 Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-1367. doi:10.1093/eurheartj/ehaa575 Open DOISearch in Google Scholar

46 Roe MT, Armstrong PW, Fox KAA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367(14):1297-1309. doi:10.1056/NEJMoa1205512 Open DOISearch in Google Scholar

47 Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015. doi:10.1056/NEJMoa0706482 Open DOISearch in Google Scholar

48 Baber U, Chandrasekhar J, Sartori S, et al. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention A Report From the PROMETHEUS Study.; 2017. Search in Google Scholar

49 James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010;122(11):1056-1067. doi:10.1161/CIRCULATIONAHA.109.933796 Open DOISearch in Google Scholar

50 Mavrakanas TA, Kamal O, Charytan DM. Prasugrel and Ticagrelor in Patients with Drug-Eluting Stents and Kidney Failure. Clin J Am Soc Nephrol. 2021;16(5):757-764. doi:10.2215/CJN.12120720 Open DOISearch in Google Scholar

51 Laine M, Lemesle G, Burtey S, et al. TicagRelor Or Clopidogrel in severe or terminal chronic kidney patients Undergoing PERcutaneous coronary intervention for acute coronary syndrome: The TROUPER trial. Am Heart J. 2020;225:19-26. doi:10.1016/j.ahj.2020.04.013 Open DOISearch in Google Scholar